Seriously ill patients stand to benefit from futuristic technologies
APL, Sweden’s largest manufacturer of fast-acting medicines and a leading contract development and manufacturing organization (CDMO), has announced a partnership with CurifyLabs, a Finnish healthtech company specializing in personalized medicine manufacturing solutions. The collaboration aims to enhance the administration of medicines to children and critically ill patients using innovative 3D printing technology.
3D printing offers significant advantages over traditional pharmaceutical processes by enabling the production of more personalized dosages and dosage forms with flexible shapes and structures. The technology allows for precise dosing, helping to reduce side effects.
Currently, APL’s manufacturing methods produce at least 100 capsules per batch. However, 3D printing technology allows them to create precise dosages, reducing waste and promoting sustainability. This automated approach also improves the working environment for staff by reducing the risk of repetitive strain injuries and limiting exposure to toxic substances.
“We are extremely impressed with CurifyLabs’ commitment to supporting our efforts to address the urgent and unmet needs of critically ill patients. 3D printing is a compelling technology well suited for improvised manufacturing, which will provide us with further opportunities to fulfill our public policy mandate,” said Erik Haeffler, CEO of APL.
Charlotta Topelius, CEO of CurifyLabs, added, “APL has demonstrated strong capabilities in high-quality, consistent, ready-to-use medicines, which is crucial in accelerating our joint development efforts. We look forward to combining our respective strengths to create even greater value for patients in need of personalized medicines.”
APL plans to offer fully compliant and validated 3D printed ready-to-use medicines to the Swedish market by 2025, with the first 3D printers due to be delivered in September 2024.
